|Title:||Polymethoxyflavones: Chemistry and Molecular Mechanisms for Cancer Prevention and Treatment||Authors:||Tung, Yen Chen
Chou, Ya Chun
Hung, Wei Lun
Cheng, An Chin
Ho, Chi Tang
|Keywords:||Anticancer | Citrus peel | Hydroxylated polymethoxyflavone | Metabolites | Polymethoxyflavone derivatives | Polymethoxyflavones||Issue Date:||15-Apr-2019||Journal Volume:||5||Journal Issue:||2||Source:||Current Pharmacology Reports||Abstract:||
© 2019, Springer Nature Switzerland AG. Polymethoxyflavones (PMFs) are one group of the flavonoid compounds, with tangeretin (Tan) and nobiletin (Nob) being the most abundant PMFs in citrus peel. Numerous biological activities of PMFs have been intensively studied, including anti-inflammatory and anticancer activities. Because of their methoxy groups, PMFs are more lipophilic than hydroxyl flavones, which may affect their biological activities. In addition, researchers found that hydroxylated PMFs (HPMFs) are one of the major metabolites of PMFs in animal urine and feces. Although PMF and HPMFs do show anticancer activity against different types of cancers, but their low hydrophilicity is still a crucial factor that may affect their biological effectiveness. Therefore, from the pharmaceutical aspect, chemical modifications of PMFs have been carried out to obtain acetylated PMFs (Ac-PMFs) for enhancing their biological effects. From the past centuries to the present, cancer is still a critical disease that needs to be solved. Carcinogenesis can be simply divided into three stages: initiation, promotion, and progression. These three stages involve different biological events, such as DNA mutation, cell proliferation, cell growth, and metastasis. In this paper, we aim to illustrate the biological effects of different PMFs, HPMFs, PMF derivatives, and metabolites against different types of cancer and related molecular mechanisms.
3',4' didemethylnobiletin; 3′ hydroxy 5,6,7,8,49 pentamethoxyflavone; 3′,4′ dihydroxy 5,6,7,8 tetramethoxyflavone; 3′,4′ dimethoxyflavone; 4' demethylnobiletin; 4′ hydroxy 5,6,7,8 tetramethoxyflavone; 4′ hydroxy 5,6,7,8,3 pentamethoxyflavone; 4′,6 dihydroxy 5,7,8 trimethoxyflavone; 4′,6,7 trihydroxy 5,8 dimethoxyflavone; 4′,7 dihydroxy 5,6,8 trimethoxyflavone; 5 hydroxy 3,6,7,8,3′,4′ hexamethoxyflavone; 5,3′,4′ didemethylnobiletin; 5,4′ didemethylnobiletin; 5,6 dihydroxy 4′,7,8 tetramethoxyflavone; 5,7 dimethoxyflavone; 6 hydroxy 40,5,7,8 tetramethoxyflavone; carboplatin; cisplatin; flavone derivative; imatinib; nobiletin; nobilitin 5,6,7,8,3',4' hexamethoxyflavone; nobilitin, 3,5,6,7,8,3′,4′ heptamethoxyflavone; paclitaxel; phenol; polymethoxyflavone; sinensetin; tangeretin; tangeretin 4',5,6,7,8 pentamethoxyflavone; unclassified drug; unindexed drug; antiinflammatory activity; antineoplastic activity; apoptosis; biological activity; cancer growth; cancer prevention; cancer therapy; carcinogenesis; cell growth; cell proliferation; chemical modification; DNA damage; drug mechanism; gene mutation; human; hydrophilicity; lipophilicity; metabolite; metastasis; nonhuman; priority journal; Review; tumor promotion
|Appears in Collections:||食品科技研究所|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.